slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 100,801-100,830
Pages 3,950
Rows per page 30
Component
100,801-100,830 of 118,471
12
Legend Biotech | Investor Presentation Deck | 14 slidesLegend Biotech | Investor Presentation Deck | 14 slides · Legend Biotech
Conference presentation Investor relations 1 hit
08
The slide uses a visual gallery of movie/TV posters to demonstrate the depth of the IP library.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
11
Slide 11 of a Lionsgate presentation.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
24
This is a standard financial disclosure slide explaining the methodology behind non-GAAP metrics used in the presentation.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank 1 hit
25
Includes footnotes explaining the basis of estimates and definitions.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank 1 hit
29
Lionsgate | SPAC Presentation Deck | 30 slidesLionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank 1 hit
01
LVMH | Results Presentation Deck | 31 slidesLVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Attention1 hit
17
LVMH | Results Presentation Deck | 31 slidesLVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Satisfaction1 hit
18
The chart uses a grouped bar structure for each region, showing Q1-Q4 and the full-year 2023 average.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Satisfaction1 hit
24
The table shows a breakdown of financial costs and adjustments, with a total net financial result change of -47 million euros.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · ActionLoop · Before After1 hit
25
The slide uses a stacked bar chart to represent the balance sheet structure.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
09
Slide highlights a strategic partnership/traction milestone.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
20
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
26
The slide contrasts the massive combined market of established CPIs ($42B) with the smaller market share of Libtayo ($0.5B) to frame the opportunity for partnership/growth.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
30
Includes details on options, warrants, and insider ownership percentages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
01
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
10
The slide uses a visual timeline/process flow to show disease progression.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
The slide uses a horizontal timeline format to map product milestones against calendar years.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
20
The slide uses a grid layout to present 10 advisors, each with a headshot, name, role, and company logo.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Team1 hit
03
The slide uses a two-column layout to contrast a specific lead asset (MAT2203) with broader pipeline opportunities.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
05
The slide uses a two-part framework: Targeting (left) and Delivery (right).Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
13
The slide uses a timeline-based case study format to demonstrate clinical efficacy and safety.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
16
The slide outlines the randomization, treatment arms, timeline, patient population criteria, and primary/secondary endpoints.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
Uses a combination of an additive equation for the value prop and a chevron-based timeline for the life cycle management.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
19
The slide uses a matrix-like structure to map disease areas (Infection, Inflammation, Oncology) to specific animal models and clinical indications.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
20
Uses a chevron-based process flow to represent maturity stages.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
21
The chart shows dose-response curves where LNC formulations consistently outperform Taxol.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The study is an ex-vivo human whole blood study using 80 ug/mL LNC and 512 ng/mL Cy5-labeled siRNA cargo.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit